Loading...

BSX BOSTON SCIENTIFIC CORP Product Launches 8-K Filing

BSTN

BSX

BOSTON SCIENTIFIC CORP

(BSX)

2025 8-K

Bonus Plan Update

Director Departure

Financial Results

Management Change

Financial Statements

Product Discontinuation

Financial Statements

Senior Notes Offering

Board Departure

Financial Results

Court Settlement

Executive Compensation

Acquisition Completed

Clinical Trial Resumption

Q3 Financial Results

Appointment of Director

Earnings Reports

Appointment of Director and...

By-Laws Amendment

Financial Results Announcement

Underwriting Agreement for ...

Appointment of Officers

Financial Results Announcement

Merger Agreement

Acquisition of Axonics, Inc.

Departure of Directors and ...

Earnings Reports

Earnings Reports

Appointment of Directors

Conversion of Preferred Stock

Annual Meeting of Stockholders

Financial Results Announcement

External Links:

On May 28, 2025, Boston Scientific Corporation announced it is discontinuing worldwide sales of the ACURATE neo2™ and ACURATE Prime™ Aortic Valve Systems due to increased regulatory requirements and expectations of financial impact, but still anticipates meeting its earnings guidance for 2025.

AI Assistant

BOSTON SCIENTIFIC CORP

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.